Sickle Cell Disease - Stroke Prevention in Nigeria Trial "SPIN"

Active, not recruiting

Phase N/A Results N/A

Summary of Purpose

Given large absolute numbers of individuals with sickle cell disease in Nigeria, hydroxyurea therapy for all individuals with sickle cell disease may not be initially feasible; however, a targeted strategy of hydroxyurea use for primary prevention of strokes is an alternative to the standard therapy (observation) for high-risk individuals. The investigators propose a feasibility study, Sickle Cell Disease -...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 28 March 2018.

1 Feb 2013 26 Feb 2013 1 Sep 2021 1 Sep 2021 1 Mar 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment


  • Michael R. DeBaun, MD, MPH